In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intercept Pharmaceuticals Inc.

www.interceptpharma.com

Latest From Intercept Pharmaceuticals Inc.

New Cash Moves NorthSea Up In NASH

With two new US investors on board, NST is financed to complete a Phase IIb trial of icosabutate in non-alcoholic steatohepatitis.

Financing Liver & Hepatic

Scrip Asks… What Does 2020 Hold For Biopharma? Part 2: Business And Investment

Executives and analysts predict trends spanning M&A, leadership diversity, curative gene therapy commercialization, biosimilars strategy and more. Expect technology innovation to continue to drive investment and deal making in biopharma.

Commercial Business Strategies

Scrip Asks…What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

 

Innovation Market Intelligence

Intercept’s Early NASH Efforts Will Stress Advanced Fibrosis

Intercept said its commercial groundwork in NASH centered on identifying doctors who treat patients with advanced fibrosis and talking to payers about the importance of preventing cirrhosis.

Business Strategies Launches
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Intercept Pharmaceuticals Inc.
  • Senior Management
  • Mark Pruzanski , MD, Pres. & CEO
    Sandip Kapadia, CFO
    David Shapiro, MD, CMO
    Jerome Durso, COO
    Jason Campagna, MD, PhD, CMO
  • Contact Info
  • Intercept Pharmaceuticals Inc.
    Phone: (646) 747-1000
    10 Hudson Yards
    37th Fl.
    New York, NY 10001
    USA
UsernamePublicRestriction

Register